[Use of partusisten in cases of placenta praevia and the incidence of respiratory distress syndrome in newborn infants].
Partusisten (Th 1165a, fenoterol) was given to 40 pregnant women aged from 19 to 39 years in whom ultrasonography demonstrated placenta praevia. Bleeding occurred between 21 and 36 weeks of pregnancy. The control group consisted of 44 pregnant women aged from 21 to 43 years not treated with partusisten. Bleeding in this group developed between 22 and 40 weeks of pregnancy. The authors conclude that partusisten use in cases of bleeding from placenta praevia in adequate doses and at adequate time make possible prolongation of pregnancy duration which increases the progression of lung maturation in the fetus and enabling reaching of relative biological maturity. This reduces the incidence of neonatal respiratory distress syndrome, and is the method of choice if genital bleeding develops prior to the 32nd week of pregnancy.
J
J
Gerber
L
L
Sozański
D000328:Adult; D005260:Female; D005280:Fenoterol / Q000627:therapeutic use*; D005325:Fetal Organ Maturity / Q000187:drug effects; D006801:Humans; D007231:Infant, Newborn; D008168:Lung / Q000196:embryology; D010923:Placenta Previa / Q000150:complications*; D011247:Pregnancy; D012127:Respiratory Distress Syndrome, Newborn / Q000209:etiology / Q000517:prevention & control*; D014592:Uterine Hemorrhage / Q000188:drug therapy* / Q000209:etiology
D005280:Fenoterol
Zastosowanie partusistenu w przypadkach łozyska przodujacego a liczba wystepujacych zespołów samoistnych zaburzeń w oddychaniu u noworodków.